Quest Diagnostics Incorporated (NYSE:DGX) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

DGX has been the topic of a number of other research reports. UBS AG reaffirmed a “buy” rating and set a $115.00 target price (up previously from $102.00) on shares of Quest Diagnostics in a report on Tuesday, April 25th. Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $122.00 target price on the stock in a report on Tuesday, June 6th. ValuEngine raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Barclays PLC reaffirmed a “hold” rating and set a $110.00 target price on shares of Quest Diagnostics in a report on Wednesday, July 19th. Finally, Mizuho upped their target price on shares of Quest Diagnostics from $115.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $109.62.

Shares of Quest Diagnostics (NYSE DGX) opened at 106.46 on Tuesday. The company’s 50 day moving average is $108.73 and its 200 day moving average is $103.30. The firm has a market cap of $14.52 billion, a price-to-earnings ratio of 21.46 and a beta of 0.69. Quest Diagnostics has a 52-week low of $79.12 and a 52-week high of $112.96.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.42 by $0.13. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. Quest Diagnostics’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.34 EPS. Analysts anticipate that Quest Diagnostics will post $5.69 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Quest Diagnostics Incorporated (NYSE:DGX) Upgraded to Hold by BidaskClub” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/quest-diagnostics-incorporated-nysedgx-upgraded-to-hold-by-bidaskclub/1488967.html.

In other news, Director Jeffrey M. Leiden sold 296 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $106.66, for a total value of $31,571.36. Following the completion of the sale, the director now owns 6,000 shares of the company’s stock, valued at approximately $639,960. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey M. Leiden sold 1,304 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $108.73, for a total transaction of $141,783.92. Following the completion of the sale, the director now directly owns 6,296 shares of the company’s stock, valued at approximately $684,564.08. The disclosure for this sale can be found here. Insiders sold a total of 61,362 shares of company stock valued at $6,600,758 in the last ninety days. 1.50% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in DGX. BlackRock Inc. boosted its stake in shares of Quest Diagnostics by 2,638.3% in the first quarter. BlackRock Inc. now owns 15,362,418 shares of the medical research company’s stock worth $1,508,435,000 after buying an additional 14,801,397 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Quest Diagnostics by 9,350.4% in the second quarter. Janus Henderson Group PLC now owns 1,451,774 shares of the medical research company’s stock worth $161,379,000 after buying an additional 1,436,412 shares during the period. AJO LP boosted its stake in shares of Quest Diagnostics by 137.9% in the second quarter. AJO LP now owns 2,134,245 shares of the medical research company’s stock worth $237,243,000 after buying an additional 1,237,021 shares during the period. Robeco Institutional Asset Management B.V. boosted its stake in shares of Quest Diagnostics by 316.2% in the second quarter. Robeco Institutional Asset Management B.V. now owns 1,043,889 shares of the medical research company’s stock worth $116,035,000 after buying an additional 793,085 shares during the period. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in shares of Quest Diagnostics during the first quarter worth about $74,201,000. 90.06% of the stock is owned by institutional investors.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.